Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Wins $2M to Validate Prostate Disease Markers, Develop Dx for Asian Consortium

NEW YORK (GenomeWeb News) — GeneNews today said it will pocket $2 million as part of a deal to develop and validate biomarkers for prostate diseases, including cancer, for an unnamed Asian biomedical consortium.
GeneNews said it will use its Sentinel Principle and Discovery Funnel technologies to find the biomarkers. If a biomarker panel is successfully validated, GeneNews will develop and market a blood-based diagnostic called ProstateSentry.
Toronto-based GeneNews said that under the agreement it will hold all of the intellectual property stemming from the research, but that the consortium will receive “certain royalties” from sales of the product.
The company has a similar blood-based diagnostic for colon cancer, called ColonSentry, in more advanced stages of development.
"While our primary focus is currently on the development of … ColonSentry, this non-dilutive investment will allow us to accelerate the development of a second product in our Sentry pipeline,” GeneNews CEO K. Wayne Marshall said in a statement.
The company did not immediately return a call seeking more information about the consortium.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.